Unicycive Therapeutics Stock Revenue
| UNCY Stock | USD 0.53 0.02 3.92% |
Unicycive Therapeutics fundamentals help investors to digest information that contributes to Unicycive Therapeutics' financial success or failures. It also enables traders to predict the movement of Unicycive Stock. The fundamental analysis module provides a way to measure Unicycive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unicycive Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 675 K | 357.7 K |
Unicycive | Revenue |
Unicycive Therapeutics Company Revenue Analysis
Unicycive Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Unicycive Therapeutics Revenue | 675 K |
Most of Unicycive Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unicycive Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Unicycive
Projected quarterly revenue analysis of Unicycive Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Unicycive Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Unicycive Therapeutics' stock price.
Unicycive Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Unicycive Therapeutics is extremely important. It helps to project a fair market value of Unicycive Stock properly, considering its historical fundamentals such as Revenue. Since Unicycive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unicycive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unicycive Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Unicycive Therapeutics reported 675 K of revenue. This is 99.99% lower than that of the Biotechnology sector and 99.91% lower than that of the Health Care industry. The revenue for all United States stocks is 99.99% higher than that of the company.
Unicycive Therapeutics is rated first in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 692,065. Unicycive Therapeutics totals roughly 675,000 in revenue claiming about 98% of equities under Health Care industry.Unicycive Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Unicycive Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Unicycive Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Unicycive Therapeutics' value.| Shares | State Street Corp | 2024-06-30 | 43.9 K | Northern Trust Corp | 2024-09-30 | 24 K | Captrust Financial Advisors | 2024-06-30 | 18.8 K | Tower Research Capital Llc | 2024-06-30 | 18.5 K | Tandem Capital Management Corp | 2024-09-30 | 15.5 K | Virtu Financial Llc | 2024-06-30 | 11.1 K | Scientech Research Llc | 2024-06-30 | 11 K | Redwood Wealth Management Group Llc | 2024-06-30 | 3 K | Bank Of America Corp | 2024-06-30 | 223 | Logos Global Management Lp | 2024-06-30 | 6.9 M | Nantahala Capital Management, Llc | 2024-06-30 | 5.6 M |
Unicycive Fundamentals
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 21.33 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Shares Owned By Insiders | 6.73 % | ||||
| Shares Owned By Institutions | 38.20 % | ||||
| Number Of Shares Shorted | 1.05 M | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) | ||||
| Cash And Equivalents | 10.57 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 811 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.43 X | ||||
| Book Value Per Share | (0.11) X | ||||
| Cash Flow From Operations | (18.28 M) | ||||
| Short Ratio | 0.74 X | ||||
| Earnings Per Share | (0.46) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.29 | ||||
| Market Capitalization | 52.87 M | ||||
| Total Asset | 14.19 M | ||||
| Retained Earnings | (64.54 M) | ||||
| Working Capital | (4.13 M) | ||||
| Net Asset | 14.19 M |
About Unicycive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Unicycive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.